Colorado BioScience Association (CBSA) highlights Colorado’s key financings and acquisitions in the industry during 2013. The Association plays a key role in promoting Colorado as a dynamic region for bioscience innovation and investment.

1.
2013
Proves
Successful
Year
for
Bioscience
in
Colorado
Colorado
BioScience
Association
(CBSA)
highlights
Colorado’s
key
financings
and
acquisitions
in
the
industry
during
2013.
The
Association
plays
a
key
role
in
promoting
Colorado
as
a
dynamic
region
for
bioscience
innovation
and
investment.
Denver,
CO
–
December
17,
2013
–
Colorado
realized
a
number
of
key
financings
and
acquisitions
in
the
bioscience
industry
during
2013.
The
announcement
is
made
by
April
Giles,
President
&
CEO
of
the
Colorado
BioScience
Association
(CBSA),
who
says
"We
saw
several
exciting
deals
this
year
with
many
more
on
the
horizon
as
Colorado
continues
to
gain
national
recognition
in
the
bioscience
industry."
CBSA
plays
a
key
role
in
promoting
Colorado
as
a
dynamic
region
for
bioscience
innovation
and
investment,
by
working
with
government
and
community
stakeholders
to
develop
ways
to
support
the
creation,
retention
and
recruitment
of
life
sciences
companies.
Highlighted
Financing
and
Acquisitions
in
2013
Include
(deals
over
$8M):
•
Biodesix
Closes
$8.8M
Series
D
Financing
-­‐
April
11,
2013
Boulder
based
Biodesix,
Inc.,
announced
that
the
company
closed
on
$8.8
million
in
a
follow-­‐on
sale
of
its
Series
D
preferred
shares.
http://www.biodesix.com/biodesix-­‐closes-­‐series-­‐d-­‐financing-­‐2/
•
Takeda
to
Acquire
Inviragen
for
$250M
–
May
8,
2013
Fort
Collins
based
Inviragen
agreed
to
be
acquired
by
Takeda,
the
largest
pharmaceutical
company
in
Japan
for
$35
million
cash
and
$215
million
in
milestones.
http://www.takeda.com/news/2013/20130508_5757.html
•
Lanx
Completes
$15M
Series
C
Equity
Financing
–
May
13,
2012
Broomfield
based
Lanx,
Inc.,
announced
the
closing
of
a
$15
million
Series
C
equity
financing.
http://www.lanx.com/pdfs/PR9900-­‐0113_Series%20C%20Equity%20Financing%20Release.pdf
•
Clovis
Oncology
Raises
an
Additional
$275M
–
June
18,
2013
Boulder
based
Clovis
Oncology’s
initial
IPO
in
2011
was
$139
million
on
the
sale
of
10.7
million
shares.
They
raised
an
additional
$75
million
in
2012
and
$275
million
in
June
of
2013
through
public
offerings.
http://www.xconomy.com/boulder-­‐denver/2013/06/18/clovis-­‐oncology-­‐closes-­‐275m-­‐offering-­‐following-­‐two-­‐pivotal-­‐weeks/
•
SomaLogic
Inc.
Raised
$10M
in
Equity
Financing
–
August
20,
2013
Boulder
based
SomaLogic
Inc.
raised
$10
million
in
equity
financing
from
unidentified
investors.
http://www.bizjournals.com/denver/blog/boosters_bits/2013/08/somalogic-­‐raises-­‐venture-­‐capital.html
•
Baxter
Completes
Acquisition
of
Gambro
AB
for
$4B
–
September
6,
2013
Lakewood
based
Gambro
BCT,
a
wholly
owned
entity
of
Gambro
AB
was
acquired
by
Baxter
International
Inc.
of
Deerfield,
Ill
for
$4
billion.
http://www.baxter.com/press_room/press_releases/2013/09_06_13_gambro.html
•
Ampio
Pharmaceuticals,
Inc.
Announces
$25M
Financing
–
September
26,
2013
Greenwood
Village
based
Ampio
Pharmaceuticals,
Inc.
(NYSE
MKT:
AMPE)
announced
a
financing
transaction
that
will
provide
$25
million
in
gross
proceeds
to
the
company.
http://ampiopharma.com/news/ampio-­‐pharmaceuticals-­‐inc-­‐announces-­‐25-­‐million-­‐financing/
-­‐More-­‐

2. Page
2
•
Surefire
Medical
Closes
Series
B
Funding
at
$18.2M
-­‐
November
7,
2013
Westminster
based
Surefire
Medical,
Inc.
completed
a
$18.2
million
Series
B
funding.
The
latest
financing
will
be
used
to
expand
product
development,
clinical
trials,
operations
and
marketing
to
meet
rapidly
growing
national
and
international
customer
demand.
http://surefiremedical.com/news/surefire-­‐medical-­‐closes-­‐series-­‐b-­‐funding-­‐at-­‐18-­‐2-­‐million/
“Large
financings
and
acquisitions
are
key
to
raising
Colorado’s
profile
to
garner
attention
from
investors
and
corporate
leadership.
Colorado
has
all
of
the
pieces
in
place
to
be
in
the
top
5
national
bioscience
clusters
in
the
country—
the
science,
the
infrastructure,
and
the
people,"
Giles
explains.
About
Colorado
BioScience
Association
Celebrating
ten
years
of
supporting
the
Bioscience
Industry
in
Colorado
in
2013,
the
CBSA
is
a
not-­‐for-­‐profit
organization
providing
services
and
support
for
Colorado's
bioscience
industry.
With
more
than
350
members,
CBSA
actively
works
to
promote
the
growth
of
the
industry
by
advocating
for
a
better
business
environment,
growing
the
state's
biotech
workforce,
fighting
for
policies
that
support
a
strong
bioscience
industry
in
the
state,
and
speaking
with
a
single
voice
on
behalf
of
the
industry.
For
more
information,
visit
http://www.cobioscience.com.
CBSA
also
is
found
on
these
social
media
sites:
Twitter:
http://www.twitter.com/COBioscience
LinkedIn
Group:
http://www.linkedin.com/groups?about=&gid=98468&trk=anet_ug_grppro
Facebook
Fan
Page:
http://www.facebook.com/ColoradoBioScienceAssociation
News
Feed:
http://coloradobio.blogspot.com
YouTube
Channel:
http://www.youtube.com/COBioscience
Pinterest:
http://pinterest.com/COBioscience
Tumblr:
http://cobioscience.tumblr.com
Contacts:
Mae
Desaire,
Director
of
Marketing,
Colorado
BioScience
Association
-­‐
http://www.cobioscience.com
–
720-­‐382-­‐5918,
mdesaire@cobioscience.com
Maggie
Chamberlin
Holben,
APR,
Absolutely
Public
Relations
-­‐
http://www.absolutelypr.com
-­‐
303-­‐984-­‐9801,
maggie@absolutelypr.com